The Express Scripts Holding (ESRX) Beats Q4 Expectations

The Express Scripts Holding Company (ESRX) reported fourth quarter non-GAAP EPS of $1.39 after the close Monday, compared to the consensus estimate of $1.38. Revenues increased 2.1% from last year to $26.31 billion. Analysts expected revenues of $25.66 billion. The stock is now down $0.49 to $86.23 on 4.78 million shares.

For Q1’15, ESRX provided EPS guidance of $1.07-$1.11 versus consensus of $1.16 per share. For the full year, the company anticipates achieving adjusted EPS in the range of $5.35 to $5.49, representing growth of 10% to 13% over 2014.

On valuation measures, Express Scripts Holding Co. shares, which currently have an average 3-month trading volume of 3.8 million shares, trade at a trailing-12 P/E of 34.87, a forward P/E of 15.94 and a P/E to growth ratio of 1.34. The median Wall Street price target on the name is $90.00 with a high target of $102.00. Currently ticker boasts 17 ‘Buy’ endorsements, compared to 7 ’Holds’ and no ‘Sell’.

Profitability-wise, ESRX has a t-12 profit and operating margin of 1.92% and 4.41%, respectively. The $63.64 billion market cap company reported $834.80 million in cash vs. $14.69 billion in debt in its most recent quarter.

ESRX currently prints a one year return of about 11.70%, and a year-to-date return of around 1.70%.

The chart below shows where the equity has traded over the last 52 weeks.

Express Scripts Holding Co. provides a range of pharmacy benefit management services primarily in the United States and Canada. The company was founded in 1986 and is headquartered in St. Louis, Missouri.

Be the first to comment

Leave a Reply

Your email address will not be published.


*